REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Wed, 23rd Oct 2019 09:29

(Alliance News) - Midatech Pharma PLC on Wednesday said it has signed a definitive binding agreement with an investor for a USD3.0 million registered direct offering.

The undisclosed "institutional investor" will pay USD1.00 each for 3.0 million American depository shares in Midatech. Each ADS represents 20 ordinary Midatech shares, meaning the offer is equivalent to 3.9 pence per ordinary share for 60.0 million ordinary shares overall.

Shares in drug delivery research and developer Midatech were down 11% at 5.00p in London on Wednesday morning.

Alongside this, Midatech will issue unregistered warrants to purchase up to another 3.0 million ADSs, with each warrant having a USD1.25 per ADS exercise price - equivalent to 4.8p per ordinary share. These warrants expire five and a half years after being issued.

The offering closes on or around Friday this week, with HC Wainright & Co acting as exclusive placement agent.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2020 16:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jan 2020 15:51

Midatech shares surge on success of latest MTD201 study

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

Read more
8 Jan 2020 09:51

Positive Headline Reading For Latest Midatech MTD201 Study

Positive Headline Reading For Latest Midatech MTD201 Study

Read more
17 Dec 2019 16:39

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Read more
5 Dec 2019 15:59

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Read more
4 Nov 2019 18:47

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Read more
24 Oct 2019 11:50

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Read more
8 Oct 2019 11:34

Midatech Doses First Patients In MTD201 Administration Method Study

Midatech Doses First Patients In MTD201 Administration Method Study

Read more
8 Oct 2019 09:24

Midatech Pharma doses first volunteers in acromegaly treatment study

(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.

Read more
7 Oct 2019 15:45

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

Read more
3 Oct 2019 15:40

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

Read more
30 Sep 2019 19:06

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Read more
24 Sep 2019 14:32

Midatech Pharma Applies To US Regulator For Share Issue Authority

Midatech Pharma Applies To US Regulator For Share Issue Authority

Read more
20 Sep 2019 15:43

Midatech Pharma gets approval for next MTD201 study

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.